BRPI0607540A2 - ensaio para a produção de circovìrus porcino - Google Patents

ensaio para a produção de circovìrus porcino

Info

Publication number
BRPI0607540A2
BRPI0607540A2 BRPI0607540-1A BRPI0607540A BRPI0607540A2 BR PI0607540 A2 BRPI0607540 A2 BR PI0607540A2 BR PI0607540 A BRPI0607540 A BR PI0607540A BR PI0607540 A2 BRPI0607540 A2 BR PI0607540A2
Authority
BR
Brazil
Prior art keywords
cells
viral
supernatant
production
methods
Prior art date
Application number
BRPI0607540-1A
Other languages
English (en)
Inventor
Patrice Allibert
Lionel Pierre Cupillard
Jean Reyes
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of BRPI0607540A2 publication Critical patent/BRPI0607540A2/pt
Publication of BRPI0607540B1 publication Critical patent/BRPI0607540B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02Recovery or purification
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/10011Circoviridae
    • C12N2750/10051Methods of production or purification of viral material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ENSAIO PARA A PRODUçãO DE CIRCOVìRUS PORCINO. A presente invenção refere-se a métodos para a determinação do título viral de uma cultura de células hospedeiras de animal infectadas com um circovírus. Os métodos baseados em FACS da invenção podem incluir a determinação da viabilidade das células hospedeiras no sobrenadante em um sobrenadante de meio de cultura celular e daquelas células que permanecem aderidas a um suporte sólido. Detectar e medir o percentual de células que expressam os antígenos virais de ORF1 e ORF2 pode determinar a carga viral das células hospedeiras cultivadas. O rendimento do vírus pode ser estabelecido pela detecção e medida de ambos os antígenos nas células sobrenadantes, por exemplo, 5 a 7 dias a partir de quando as células hospedeiras são transferidas para um meio livre de soro. Os métodos da invenção podem fornecer dados quantitativos rápidos. Isso permite o monitoramento em andamento repetido da produção viral através do período de incubação e pronta seleção do ponto de coleta mais apropriado.
BRPI0607540A 2005-04-13 2006-04-13 ensaio para a produção de circovírus porcino BRPI0607540B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67089205P 2005-04-13 2005-04-13
PCT/US2006/014068 WO2006113435A2 (en) 2005-04-13 2006-04-13 Method for porcine circovirus production and assays for monitoring production

Publications (2)

Publication Number Publication Date
BRPI0607540A2 true BRPI0607540A2 (pt) 2009-09-15
BRPI0607540B1 BRPI0607540B1 (pt) 2017-05-09

Family

ID=37115731

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607540A BRPI0607540B1 (pt) 2005-04-13 2006-04-13 ensaio para a produção de circovírus porcino

Country Status (20)

Country Link
US (2) US7358075B2 (pt)
EP (2) EP3088893B1 (pt)
JP (1) JP5408998B2 (pt)
KR (1) KR101369656B1 (pt)
CN (1) CN101194165B (pt)
BR (1) BRPI0607540B1 (pt)
CA (1) CA2604691C (pt)
CR (1) CR9511A (pt)
CY (1) CY1117850T1 (pt)
DK (1) DK1869471T3 (pt)
ES (1) ES2589928T3 (pt)
HR (1) HRP20161132T1 (pt)
HU (1) HUE028343T2 (pt)
ME (1) ME02683B (pt)
MX (1) MX2007012786A (pt)
PL (1) PL1869471T3 (pt)
PT (1) PT1869471T (pt)
RS (1) RS55085B1 (pt)
SI (1) SI1869471T1 (pt)
WO (1) WO2006113435A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US20080226594A1 (en) * 2005-02-03 2008-09-18 Hans Nauwynck Culturing circular ssdna viruses for the production of vaccines
EP1968630B1 (en) 2005-12-29 2018-01-24 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions
MX338626B (es) 2005-12-29 2016-04-26 Boehringer Ingelheim Vetmed Uso de una composicion inmunogenica de pcv2 para producir los sintomas clinicos en cerdos.
EP2859900A1 (en) * 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
JP5200223B2 (ja) * 2006-12-15 2013-06-05 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド Pcv2抗原によるブタの処置
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US8502920B2 (en) * 2007-03-14 2013-08-06 Vyacheslav Shyshkin Method and apparatus for extracting a desired television signal from a wideband IF input
CN101688185B (zh) 2007-05-11 2013-05-22 淡马锡生命科学研究院有限公司 对2型猪环状构象病毒(pcv2)感染高度容许的均质细胞系的产生
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
WO2009088950A2 (en) * 2007-12-31 2009-07-16 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 virus like particle with foreign amino acid insertion
KR20100113582A (ko) * 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Pcv2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
CN101773667A (zh) * 2010-01-28 2010-07-14 洛阳普莱柯生物工程有限公司 一种猪圆环病毒ii型疫苗制备
CN102690790B (zh) * 2012-04-27 2013-09-25 成都天邦生物制品有限公司 猪圆环病毒2型细胞悬浮培养生产方法
ES2882374T3 (es) 2013-05-08 2021-12-01 Pharmgate Biologics Inc Vacuna para PCV2 y micoplasma
EP3049106A1 (en) 2013-09-25 2016-08-03 Zoetis Services LLC Pcv2b divergent vaccine composition and methods of use
US9505808B2 (en) 2013-10-02 2016-11-29 Boehringer Ingelheim Vetmedica, Inc. PCV2 ORF2 protein variant and virus like particles composed thereof
WO2017019404A1 (en) 2015-07-24 2017-02-02 Merial, Inc. High throughput methods for virus quantification
DE102018100967B4 (de) 2018-01-17 2019-08-14 Immatics US, Inc. Verfahren zur feststellung der wirksamkeit von viralen vektoren
DE102018010282A1 (de) 2018-01-17 2019-07-18 Immatics US, Inc. Verfahren zur Feststellung der Wirksamkeit von viralen Vektoren

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
UA78180C2 (uk) * 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
EP1111040A1 (en) * 1999-12-10 2001-06-27 Daniel Favre Infection of eukaryotic cells with viruses in vitro
JP2004503234A (ja) * 2000-06-15 2004-02-05 パーデュー・リサーチ・ファウンデーション ブタの先天性振せん用ワクチン
DE10044648A1 (de) * 2000-09-08 2002-03-21 Aventis Behring Gmbh Verfahren zur Vermehrung oder zur Entfernung von Cirocoviren aus biologischem Material
EP2287288B1 (en) * 2002-07-09 2012-11-07 Baxter International Inc. Animal protein free media for cultivation of cells
EP2481819A1 (en) * 2003-02-25 2012-08-01 MedImmune Vaccines, Inc. Cross flow filtration in the production of stabilized influenza vaccine compositions

Also Published As

Publication number Publication date
CN101194165B (zh) 2013-01-09
US7476507B2 (en) 2009-01-13
MX2007012786A (es) 2008-01-11
JP5408998B2 (ja) 2014-02-05
JP2008536499A (ja) 2008-09-11
RS55085B1 (sr) 2016-12-30
WO2006113435A3 (en) 2007-06-21
KR101369656B1 (ko) 2014-03-04
CN101194165A (zh) 2008-06-04
EP1869471A2 (en) 2007-12-26
HUE028343T2 (en) 2016-12-28
CA2604691C (en) 2013-12-31
US20060246425A1 (en) 2006-11-02
EP3088893B1 (en) 2018-02-14
BRPI0607540B1 (pt) 2017-05-09
HRP20161132T1 (hr) 2016-12-02
EP1869471B1 (en) 2016-06-08
HK1121232A1 (en) 2009-04-17
PT1869471T (pt) 2016-08-16
KR20070120603A (ko) 2007-12-24
WO2006113435A2 (en) 2006-10-26
ME02683B (me) 2017-06-20
CA2604691A1 (en) 2006-10-26
DK1869471T3 (en) 2016-08-01
ES2589928T3 (es) 2016-11-17
PL1869471T3 (pl) 2017-02-28
US20080241821A1 (en) 2008-10-02
EP3088893A1 (en) 2016-11-02
CY1117850T1 (el) 2017-05-17
US7358075B2 (en) 2008-04-15
CR9511A (es) 2008-01-29
SI1869471T1 (sl) 2016-09-30

Similar Documents

Publication Publication Date Title
BRPI0607540A2 (pt) ensaio para a produção de circovìrus porcino
Lamb et al. Dissecting tumor metabolic heterogeneity: Telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells
Russell et al. Clonal analysis of the proliferation potential of human bone marrow mesenchymal stem cells as a function of potency
BRPI0922572A2 (pt) método para cultivar células pluripotentes, cultura de células de mamífero pluripotentes, meio de cultura de célula, célula animal pluripotente isolada, e, método para aumentar a pluripotência de uma célula de mamífero.
Lebeau et al. The trypan blue cellular debris assay: a novel low-cost method for the rapid quantification of cell death
EA201101581A1 (ru) Улучшенный способ культивирования клеток
Hallgren et al. Granule maturation in mast cells: histamine in control
BR112014027378A2 (pt) expressão transiente de alto rendimento em células de mamíferos usando pareamento exclusivo de crescimento de alta densidade e meio de transfecção e potenciadores de expressão
Lai et al. Apoptosis induction by pseudorabies virus via oxidative stress and subsequent DNA damage signaling
RU2019138327A (ru) Способы перфузионного культивирования и их применения
BR112022010816A2 (pt) Métodos para melhoramento de crescimento celular com proteínas específicas de espécie ou específicas de gênero e aplicações dos mesmos
Mendonça et al. Metabolic active-high density VERO cell cultures on microcarriers following apoptosis prevention by galactose/glutamine feeding
CN101975768A (zh) 腹泻性贝类毒素检测方法
Krešić et al. Canine adipose derived mesenchymal stem cells transcriptome composition alterations: a step towards standardizing therapeutic
BR112014020513A2 (pt) Métodos e sistemas para amplificação de sinal de bioensaios
Manohar et al. Combining fluorescent cell barcoding and flow cytometry‐based phospho‐ERK1/2 detection at short time scales in adherent cells
Matos Isolation, taxonomic identification and investigation of the biotechnological potential of wild-type Meyerozyma guilliermondii associated with amazonian termites able to ferment D-xylose= Isolamento, identificação taxonômica e investigação
JP2008516604A5 (pt)
ATE499598T1 (de) Markierungsfreier einzelzelltest
Domingues et al. Cellular prion protein PrPC and Ecto-5′-Nucleotidase are markers of the cellular stress response to aneuploidy
AR086043A1 (es) Sistema de ensayo y metodos para identificar un compuesto que altera la actividad celular del ddr
GB0503172D0 (en) Detection method
Someya et al. Establishment of measles virus receptor‐expressing Vero cells lacking functional poliovirus receptors
Zhang et al. Koisio technology-modulated cell culture media can significantly increase the antioxidant capacity of mouse fibroblasts
CN105920580B (zh) 海洋微生物来源化合物p-3在制备抗衰老药物中的应用

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: MERIAL, INC. (US)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]
B25A Requested transfer of rights approved